influenza
viru
affect
approxim
popul
everi
season
healthi
individu
infect
predominantli
result
rel
mild
selflimit
diseas
remain
restrict
upper
respiratori
tract
requir
therapeut
intervent
reflect
overal
high
diseas
preval
howev
world
health
organ
estim
million
infect
lead
sever
diseas
advanc
lower
respiratori
tract
viral
pneumonia
result
death
annual
highrisk
group
sever
influenza
infect
includ
older
adult
immunocomprom
pregnant
women
peopl
underli
pulmonari
condit
lesser
degre
young
yearli
vaccin
recommend
everyon
older
month
age
vaccin
efficaci
vari
substanti
base
well
circul
virus
vaccin
strain
match
patient
age
patient
influenza
histori
influenza
season
instanc
vaccin
efficaci
predomin
strain
lead
highest
mortal
rate
sinc
pandem
although
diseas
burden
particularli
high
season
vaccin
efficaci
averag
also
preced
year
also
moreov
effect
influenza
vaccin
particularli
low
older
adult
leav
one
primari
atrisk
group
poorli
protect
review
due
limit
vaccin
prophylaxi
combin
continu
high
diseas
burden
caus
season
influenza
virus
threat
spillov
highli
pathogen
avian
influenza
virus
human
popul
low
barrier
viral
escap
standardofcar
therapeut
discuss
detail
effect
novel
antivir
therapeut
urgent
need
improv
diseas
manag
especi
high
risk
patient
heighten
prepared
risk
futur
global
pandem
wherea
influenza
viru
infect
caus
direct
cell
damag
airway
epithelium
sever
tissu
damag
complic
diseas
larg
consequ
immunopathogenesi
peak
acut
infect
clear
influenza
viru
load
upper
respiratori
tract
highest
approxim
day
infect
coincid
peak
fever
pronounc
respiratori
clinic
sign
third
day
infect
viru
replic
increasingli
immun
control
viru
load
drop
rapidli
rapid
diseas
progress
case
uncompl
diseas
immun
control
viru
replic
outlin
narrow
therapeut
window
influenza
drug
ideal
treatment
initi
within
hour
infect
fact
clinic
studi
assess
impact
neuraminidas
inhibitor
nai
reveal
benefit
patient
treatment
initi
within
hour
onset
influenza
symptom
therapeut
impact
greatest
antivir
drug
administ
within
hour
diseas
manifest
accordingli
public
diseas
awar
proactiv
patient
behavior
access
rapid
diagnost
paramount
therapeut
success
sever
diagnost
method
current
use
clinic
shorten
time
treatment
recent
compar
review
attempt
preempt
challeng
aris
narrow
therapeut
window
chemoprophylaxi
explor
wherea
sever
studi
support
prophylact
administr
nai
lower
risk
develop
diseas
cdc
recommend
reserv
chemoprophylaxi
peopl
high
risk
group
outbreak
control
among
high
risk
individu
institut
set
contrast
gener
chemoprophylaxi
recommend
due
unclear
riskbenefit
otherwis
healthi
patient
concern
promot
develop
viral
resist
current
approv
influenza
drug
interfer
viral
protein
function
therefor
belong
group
directact
antivir
daa
comparison
indirectli
act
hostdirect
experiment
antivir
drug
daa
group
lower
tendenc
undesir
side
effect
howev
rapid
develop
viral
resist
emerg
predomin
liabil
daa
especi
direct
rna
virus
error
prone
polymeras
respiratori
syncyti
viru
rsv
influenza
virus
exemplifi
scope
problem
adamantan
amantadin
subsequ
rimantadin
first
drug
approv
treatment
influenza
viru
iav
infect
inhibitor
target
viral
ion
channel
prevent
dissoci
viral
ribonucleoprotein
rnp
genom
matrix
protein
block
diffus
proton
virion
locat
matur
endosom
iav
strain
also
affect
virion
assembl
disturb
phequilibr
late
golgi
howev
administr
adamant
discourag
cdc
decad
due
widespread
preexist
viral
resist
influenza
season
instanc
circul
strain
carri
resist
mutat
amantadin
high
preval
resist
adamantan
thought
directli
reflect
extens
use
poultri
industri
also
increas
risk
prolong
exposur
human
virus
drug
sinc
adamantan
detect
agricultur
anim
day
treatment
addit
season
influenza
viru
strain
signatur
amantadin
resist
mutat
detect
highli
pathogen
avian
strain
lower
risk
trigger
emerg
resist
influenza
drug
class
circul
virus
mani
countri
includ
unit
state
china
ban
use
agricultur
past
decad
major
research
effort
direct
toward
discoveri
hostdirect
antivir
drug
lure
prospect
high
barrier
therapeut
develop
resist
mechanist
uniqu
hostdirect
viral
entri
inhibitor
recombin
sialidas
fusion
protein
target
cellular
sialic
acid
residu
requir
influenza
viru
infect
contrast
extracellular
host
target
major
experiment
hostdirect
antivir
aim
modul
host
immun
respons
develop
intracellular
process
critic
success
viru
replic
review
challeng
howev
identif
druggabl
intracellular
target
major
impact
viru
replic
translat
research
dispens
host
function
reflect
conundrum
antivir
efficaci
undesir
advers
effect
hostdirect
antivir
follow
case
structureact
relationship
intracellularli
act
hostdirect
candid
approv
yet
clinic
use
influenza
virus
respiratori
rna
virus
myxoand
pneumoviru
famili
tabl
show
influenza
drug
current
approv
recommend
clinic
use
neuraminidas
inhibitor
nai
clinic
use
oseltamivir
fig
peramivir
zanamivir
oseltamivir
carboxyl
frequent
prescrib
consid
standardofcar
influenza
manag
sinc
essenti
circul
influenza
virus
acquir
resist
adamantan
mechanist
nai
competit
inhibit
enzymat
activ
iav
influenza
b
viru
ibv
neuraminidas
prevent
cleavag
termin
sialic
acid
residu
glycoprotein
carbohydr
display
surfac
mammalian
cell
influenza
viru
particl
bind
virion
uncleav
sialic
acid
impair
virion
releas
dissemin
oseltamivir
oral
bioavail
welltoler
reflect
excel
safeti
profil
drug
approv
use
also
pregnant
women
pediatr
patient
neonat
discuss
clinic
trial
shown
nai
provid
benefit
start
earli
infect
howev
metaanalys
clinic
data
reveal
littl
effect
reduc
influenzaassoci
complic
hospit
data
suggest
late
treatment
nai
could
enhanc
risk
progress
sever
diseas
pandem
resist
oseltamivir
develop
rapidli
experiment
set
clinic
typic
origin
substitut
signatur
resist
site
viral
na
protein
predomin
virus
predomin
virus
major
resist
mutat
zanamivir
na
substitut
virus
virus
respect
wherea
resist
nai
rel
rare
current
endem
influenza
viru
strain
preval
escap
mutat
increas
rapidli
influenza
season
approxim
strain
circul
season
resist
nai
gener
concern
drug
class
could
also
lost
resist
futur
neutral
antibodi
although
biolog
approv
influenza
therapi
far
neutral
antibodi
nab
particular
extens
test
substanti
preced
establish
instanc
nab
use
clinic
rsv
ebola
viru
infect
antibodybas
therapeut
typic
welltoler
show
favor
pharmacokinet
profil
influenza
viru
ha
head
domain
contain
receptor
bind
site
rbc
highli
immunogen
thu
primari
target
nab
howev
headdirect
antiinfluenza
nab
typic
show
narrow
indic
spectrum
hamper
clinic
develop
although
nab
direct
conserv
rbc
identifi
altern
target
less
variabl
stalk
domain
ha
trimer
attract
major
attent
recent
year
due
crossreact
multipl
ha
subtyp
three
influenza
viru
ha
stalktarget
broadli
neutral
ab
bnab
advanc
phase
clinic
trial
demonstr
antivir
efficaci
dose
therapeut
acceler
symptom
resolut
reduc
viru
replic
halflif
approxim
week
human
make
therapeut
antibodi
compat
attract
singledos
administr
wherea
resist
virus
emerg
clinic
trial
viral
escap
pathway
ha
stalkdirect
antibodi
identifi
experiment
viral
adapt
cell
cultur
resist
variant
either
carri
point
mutat
stalk
epitop
prevent
antibodi
bind
harbor
substitut
enhanc
ha
fusion
activ
therefor
allow
viral
entri
presenc
antibodi
experiment
resist
mutat
affect
viral
fit
howev
reduc
viral
replic
cell
cultur
major
concern
use
broadli
reactiv
ab
uncompl
season
influenza
target
restrict
iav
lack
oral
bioavail
necess
highdos
inject
consequ
poor
distribut
blood
upper
airway
high
manufactur
cost
biolog
sinc
iav
ibv
human
pathogen
clinic
relev
efficaci
pathogen
genera
constitut
development
object
nextgener
drug
target
breadth
achiev
tradit
bnab
howev
engin
multidomain
antibodi
explor
experiment
proofofconcept
efficaci
iav
ibv
demonstr
mice
potenti
illumin
path
overcom
limit
furthermor
better
complianc
larg
patient
group
nonhospit
adult
suffer
uncompl
diseas
expect
drug
oral
bioavail
amen
costeffect
manufactur
bnab
appear
therefor
best
suit
use
high
risk
group
hospit
patient
complic
diseas
inhibitor
viral
polymeras
complex
last
decad
viral
rnadepend
rna
polymeras
rdrp
complex
emerg
import
target
novel
smallmolecul
therapeut
progress
advanc
develop
andor
clinic
test
influenza
viru
rdrp
compris
subunit
pa
protein
respons
replic
transcript
genom
segment
segment
exist
nake
rna
encapsid
viral
np
protein
form
rnp
complex
wherea
replic
requir
gener
complementari
posit
polar
rna
intermedi
crna
copi
progeni
neg
polar
segment
vrnp
viral
messag
directli
synthes
vrnp
sinc
influenza
viru
rdrp
lack
enzymat
activ
form
mrna
cap
structur
endonucleas
activ
pa
subunit
instrument
gener
bioactiv
viral
mrna
transfer
cap
rna
primer
deriv
host
mrna
capsnatch
mechan
involv
bind
cap
primer
wherea
subunit
harbor
enzymat
activ
phosphodiest
bond
format
overal
replic
strategi
rdrp
organ
highli
conserv
across
iav
subtyp
among
iav
ibv
increas
likelihood
therapeut
target
polymeras
complex
result
develop
broadspectrum
influenza
viru
inhibitor
baloxavir
marboxil
found
member
pa
endonucleas
inhibitor
class
licens
japan
unit
state
sinc
baloxavir
marboxil
fig
first
new
influenza
drug
class
approv
decad
treatment
uncompl
influenza
infect
patient
older
year
age
taken
oral
baloxavir
marboxil
prodrug
prevent
capsnatch
block
pa
endonucleas
activ
hydrolyz
free
baloxavir
acid
singl
dose
typic
suffici
clinic
benefit
efficaci
similar
better
current
standardofcar
clinic
trial
particip
show
significantli
lower
viral
burden
day
initi
treatment
compar
placebo
group
time
allevi
clinic
sign
decreas
averag
approxim
hour
resembl
improv
achiev
nai
quit
remark
twice
daili
experiment
treatment
mice
infect
lethal
dose
highli
pathogen
avian
iav
result
complet
surviv
anim
reduct
viral
load
respiratori
tract
similarli
profound
efficaci
observ
immunocomprom
mice
addit
activ
iav
ibv
influenza
virus
c
genera
suscept
baloxavir
inhibit
make
drug
truli
broadspectrum
influenza
viru
inhibitor
baloxavir
marboxil
well
toler
clinic
trial
mild
transient
advers
event
translat
research
resolv
without
intervent
side
effect
includ
headach
increas
eosinophil
white
blood
cell
count
pk
properti
pediatr
recipi
similar
seen
adult
trial
involv
pediatr
patient
receiv
weightadjust
dose
baloxavir
marboxil
establish
equival
efficaci
adult
children
uncompl
influenza
although
efficaci
baloxavir
marboxil
nai
compar
baloxavir
marboxil
provid
full
benefit
singl
oral
dose
give
drug
advantag
current
standardofcar
consist
distinct
protein
target
baloxavir
marboxil
nai
virus
harbor
signatur
nai
resist
mutat
shown
remain
suscept
inhibit
baloxavir
marboxil
despit
excit
safeti
efficaci
perform
baloxavir
marboxil
resist
virus
emerg
adult
clinic
trial
particip
children
sever
case
emerg
resist
coincid
rebound
shed
viru
titer
prolong
manifest
clinic
sign
resembl
resist
profil
gener
differ
pa
endonucleas
inhibitor
chemotyp
cell
cultur
signatur
hotspot
escap
baloxavir
marboxil
pa
residu
sever
substitut
pa
describ
initi
character
pa
mutant
virus
cell
cultur
suggest
resist
may
carri
sever
fit
penalti
howev
subsequ
followup
analys
fit
strain
contain
pa
mutant
ferret
model
reveal
pathogenesi
transmiss
success
resist
correspond
sensit
virus
equival
mice
ferret
loss
anim
bodi
weight
lung
viral
load
ident
infect
resist
sensit
virus
substitut
pa
remain
stabl
passag
mice
small
percentag
influenza
virus
circul
unit
state
season
thu
prior
approv
baloxavir
marboxil
contain
mutat
pa
residu
moreov
resist
viru
detect
pediatr
patient
without
prior
exposur
baloxavir
marboxil
support
mutant
strain
spread
human
even
though
baloxavir
marboxil
yet
use
extens
clinic
longterm
field
data
scarc
avail
evid
indic
genet
barrier
resist
drug
low
escap
come
littl
penalti
viral
fit
pathogenesi
transmiss
success
accordingli
consider
risk
preexit
resist
baloxavir
marboxil
could
becom
widespread
increas
durat
clinic
use
favipiravir
broadspectrum
ribonucleosid
analog
inhibitor
rna
virus
broadspectrum
pyrazinecarboxamid
fig
convert
intracellularli
ribonucleosid
analog
phosphoribosyl
thu
competit
target
viral
rdrp
complex
anabol
effici
vari
cell
differ
tissu
origin
shown
low
diseaserelev
primari
human
airway
epithelium
cell
drug
broadspectrum
antivir
activ
cell
cultur
inhibit
rna
virus
arenaviru
bunyaviru
flaviviru
alphaviru
noroviru
picornaviru
paramyxoviru
rhabdoviru
famili
addit
influenza
virus
mechanist
incorpor
newli
synthes
rna
viral
polymeras
place
purin
pyrimidin
result
increas
frequenc
ctou
gtoa
transit
mutat
demonstr
influenza
virus
hepat
c
viru
vitro
vivo
collaps
viru
replic
consid
consequ
error
catastroph
lethal
mutagenesi
result
accumul
random
lowfrequ
mutat
viral
genom
fig
genet
barrier
resist
favor
high
although
recent
studi
identifi
pair
point
mutat
pa
polymeras
subunit
reduc
viral
sensit
compound
approxim
cell
cultur
safeti
test
reveal
teratogen
embryotox
concentr
close
approv
human
dose
although
condit
licens
japan
treatment
pathogen
influenza
virus
resist
therapeut
safeti
concern
prevent
drug
administr
highrisk
group
children
pregnant
women
activ
assess
potenti
viral
target
anim
model
furthermor
reveal
vivo
efficaci
quit
poor
depend
extrem
high
dose
concentr
result
lower
clinic
valu
undermin
use
virus
predominantli
associ
pediatr
diseas
pathogen
pneumoviru
paramyxoviru
famili
nextgener
influenza
viru
inhibitor
candid
earli
develop
search
inhibitor
broad
antirespiratori
rna
viru
activ
yield
ribonucleosid
analog
n
hydroxycytidin
nhc
show
oral
efficaci
rsv
highlypathogen
avian
season
influenza
virus
mous
model
mechanist
character
reveal
compound
effici
anabol
bioactiv
triphosph
form
ex
vivo
primari
human
airway
epithelium
cultur
anim
tissu
follow
incorpor
cytidin
viral
rna
influenza
viru
polymeras
tautomer
interconvers
caus
basepair
incorpor
analog
either
cytosin
uracil
result
highfrequ
random
ctou
gtoa
transit
mutat
viral
rna
replic
transcript
product
thu
inhibit
error
catastroph
addit
studi
expand
antivir
target
spectrum
nhc
virus
flaviviru
alphaviru
coronaviru
togaviru
famili
demonstr
broad
antirna
viru
activ
wherea
rodent
pk
properti
nhc
good
oral
bioavail
drug
nonhuman
primat
cynomolgu
macaqu
limit
liabil
address
develop
prodrug
isopropylest
fig
nhc
demonstr
good
oral
bioavail
speci
test
includ
nonhuman
primat
upon
intestin
absorpt
effici
hydrolyz
free
nhc
oral
daili
dose
mgkg
reportedli
efficaci
iav
strain
ferret
model
caus
signific
reduct
viral
load
upper
lower
respiratori
tract
allevi
clinic
sign
compound
show
potent
antivir
activ
diseaserelev
welldifferenti
human
airway
epithelium
model
cultur
inhibit
iav
ibv
strain
activ
concentr
around
mm
select
indic
appear
establish
unusu
high
barrier
viral
resist
sinc
sever
studi
unsuccess
tri
induc
viral
escap
doseescal
subleth
fixeddos
adapt
strategi
nextgener
sequenc
result
treatmentexperienc
viru
popul
reveal
elev
number
lowfrequ
mutat
none
becam
alleledomin
mediat
robust
resist
drug
although
result
encourag
adapt
serial
passag
vivo
like
necessari
better
predict
whether
resist
nhc
could
ultim
emerg
toxic
concern
major
potenti
liabil
ribonucleosid
analog
underscor
instanc
compromis
safeti
profil
primari
sourc
advers
effect
incorpor
ribonucleosid
analog
host
rna
nuclear
mitochondri
rna
polymeras
integr
mitochondri
transcript
particularli
risk
due
proofread
inabl
mitochondri
rna
polymeras
contrast
nuclear
rna
pol
ii
surprisingli
nhc
incorpor
human
mitochondri
polymeras
vitro
studi
elev
frequenc
nhccharacterist
transit
event
note
prolong
exposur
primari
human
airway
epithelium
cell
drug
howev
transit
mutat
frequenc
ferret
lung
tissu
unchang
control
extend
treatment
anim
mgkg
daili
dose
thu
efficaci
dose
influenza
therapi
potenti
advers
effect
embryo
develop
untest
present
formal
multidos
toxic
studi
requir
establish
initi
human
dose
examin
phase
clinic
trial
pimodivir
inhibitor
clinic
develop
pimodivir
cyclohexyl
carboxyl
acid
analogu
fig
translat
research
target
polymeras
subunit
drug
outperform
current
standardofcar
anim
infect
model
virus
although
potenc
highest
strain
also
pimodivir
remain
activ
virus
harbor
signatur
resist
mutat
nai
presum
low
risk
crossresist
baloxavir
marboxil
well
compound
welltoler
phase
clinic
trial
reduc
viral
load
result
slightli
faster
resolv
clinic
sign
howev
specif
resist
mutat
pimodivir
emerg
protein
trial
particip
indic
genet
barrier
viral
escap
drug
low
compar
standardofcar
baloxavir
marboxil
ribonucleosid
analog
develop
anoth
substanti
limit
pimodivir
narrow
antivir
indic
spectrum
exclus
iav
suscept
drug
restrict
use
clinicallysignific
influenza
viru
genera
influenza
virus
continu
present
major
threat
human
health
global
past
year
first
new
drug
class
decad
approv
influenza
therapi
provid
muchneed
expans
avail
antivir
arsen
howev
low
genet
barrier
neuraminidas
pa
endonucleas
inhibitor
viral
escap
creat
urgent
need
nextgener
therapeut
differ
development
candid
current
explor
bnab
attract
protect
highrisk
group
treatment
cost
manag
competit
ribonucleosid
analog
inhibitor
high
resist
barrier
promis
use
season
pandem
virus
provid
risk
advers
effect
accept
low
appropri
mitig
